The dyslipidemia of chronic renal disease: Effects of statin therapy

Current Opinion in Lipidology

Volumn 17, Issue 6, 2006, Pages 659-666

  Ozsoy, Riza C ^a   Van Leuven, Sander I ^a   Kastelein, John J P ^a   Arisz, Lambertus ^a   Koopman, Marion G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Creatinine clearance; Dyslipidemia; Proteinuria; Renal failure; Statins

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; CREATININE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; PROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DYSLIPIDEMIA; EARLY DIAGNOSIS; GENETIC POLYMORPHISM; GLOMERULONEPHRITIS; HEART PROTECTION; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BLOOD FLOW; MICROALBUMINURIA; PLEIOTROPY; POST HOC ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; PROTEINURIA;

EID: 33750908088     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328010a87d     Document Type: Review

References (100)

1. Trivedi HS, Pang MMH, Campbell A, Saab P. Slowing the progression of chronic renal failure: Economic benefits and patients' perspectives. Am J Kidney Dis 2002; 39:721-729.
2. Dirks JH, de Zeeuw D, Agarwal SK, et al. Prevention of chronic kidney and vascular disease: Toward global health equity - The Bellagio 2004 Declaration. Kidney Int 2005; 68:S1-S6.
3. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third national health and nutrition examination survey. Am J Kidney Dis 2003; 41:1-12.
4. Hillege HL, Janssen WM, Bak AA, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249:519-526.
5. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777-1782.
6. Gerstein HC, Mann JFE, Yi Q, et al., for the HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc 2001; 286:421-426.
7. Weiner DE, Tighiouart H, Stark PC, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004; 44:198-206.
8. O'Hare AM, Glidden DV, Fox CS, Hsu CY. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. Circulation 2004; 109:320-323.
9. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
10. Hostetter TH. Chronic kidney disease predicts cardiovascular disease. N Engl J Med 2004; 351:1344-2134.
11. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003; 108:2154-2169.
12. Keane W, Eknoyan G. Proteinuria, Albuminuria, Risk, Assessment, Detection, Elimination (PARADE): A Position Paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33:1004-1010.
13. Stichting Renine. Statistisch Jaarverslag 1998. Rotterdam; 1998.
14. US Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2000 Annual Data Report. Bethesda, MD; 2000.
15. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; 61:297-304.
16. Wanner C, Krane V, Marz W, et al., the German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238-248. Randomized trial which reported that statin therapy did not reduce cardiovascular risk in patients who have advanced to ESRD.
17. Massy ZA, Khoa TN, Lacour B, et al. Dyslipidaemia and the progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant 1999; 14:2392-2397.
18. Batista MC, Welty FK, Diffenderfer MR, et al. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. Metabolism 2004; 53:1255-1261.
19. Muntner P, Hamm LL, Kusek JW, et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140:9-17.
20. Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; 2:1309-1311.
21. Ozsoy RC, Kastelein JJ, Arisz L, Koopman MG. Atorvastatin and the dyslipidemia of early renal failure. Atherosclerosis 2003; 166:187-194.
22. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685-696.
23. Pedersen TR, Olsson AG, Furgeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97:1453-1460.
24. Shepherd J, Cobbe SM, Ford I, et al., The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1308.
25. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101:477-484.
26. Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005; 112:171-178. Post-hoc analysis reporting statin induced favorable renal outcome.
27. Levin A. Consequences of late referral on patient outcomes. Nephrol Dial Transplant 2000; 15 (Suppl 3):8-13.
28. De Nicola L, Minutolo R, Chiodini P, et al. Global approach to cardiovascular risk in chronic kidney disease: Reality and opportunities for intervention. Kidney Int 2006; 69:538-545. Cross-sectional study reporting that dyslipidemia is widespread in patients with renal disease, but is largely left untreated.
29. Muntner P, He J, Astor BC, et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 2005; 16:529-538. Post-hoc analysis reporting that dyslipidemia is widespread in patients with renal impairment and contributes to cardiovascular risk.
30. Pentikainen MO, Oksjoki R, Oorni K, Kovanen PT. Lipoprotein lipase in the arterial wall: linking LDL to the arterial extracellular matrix and much more. Arterioscler Thromb Vasc Biol 2002; 22:211-217.
31. Zhang L, Lookene A, Wu G, Olivecrona G. Calcium triggers folding of lipoprotein lipase into active dimers. J Biol Chem 2005; 280:42580-42591.
32. Sato T, Liang K, Vaziri ND. Down-regulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis. Kidney Int 2002; 61:157-162.
33. Barter P, Kastelein J, Nunn A, Hobbs R. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 2003; 168:195-211.
34. Kimura H, Miyazaki R, Imura T, et al. Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels. Kidney Int 2003; 64:1829-1837.
35. Kuivenhoven JA, Pritchard H, Hill J, et al. The molecular pathology of lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 1997; 38:191-205.
36. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001; 135:447-459.
37. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358:2026-2033.
38. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-952.
39. Walldius G, Jungner I, Aastveit AH, et al. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004; 42:1355-1363.
40. Moulin P, Appel GB, Ginsberg HN, Tall AR. Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: role in dyslipidemia. J Lipid Res 1992; 33:1817-1822.
41. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006; 290:F262-F272. Review on etiology of renal dyslipidemia.
42. Boekholdt SM, Kuivenhoven JA, Wareham NJ, et al., Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women. The Prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk Population Study. Circulation 2004; 110:1418-1423.
43. Agarwal R, Curley TM. The role of statins in chronic kidney disease. Am J Med Sci 2005; 330:69-81.
44. Campese VM, Nadim MK, Epstein M. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol 2005; 16 (Suppl 1):S11-S17.
45. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356:147-152.
46. Vaziri ND, Liang K, Parks JS. Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome. Am J Physiol Renal Physiol 2001; 280:F823-F828.
47. Vaziri ND, Liang K, Parks JS. Down-regulation of hepatic lecithin: cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int 2001; 59:2192-2196.
48. Shearer GC, Kaysen GA. Proteinuria and plasma compositional changes contribute to defective lipoprotein catabolism in the nephrotic syndrome by separate mechanisms. Am J Kidney Dis 2001; 37:S119-S122.
49. Shearer GC, Stevenson FT, Atkinson DN, et al. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney Int 2001; 59:179-189.
50. Vaziri ND. Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int 2003; 63:1964-1976.
51. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-2016.
52. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000; 102:1893-1900.
53. Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2005; 45:473-484. Randomized trial on statin effectiveness in reducing dyslipidemia and statin safety in patients with renal disease.
54. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41 (Suppl 3):1-91.
55. Tonelli M, Keech A, Shepherd J, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 2005; 16:3748-3754. Post-hoc analysis reporting statin induced reduction of cardiovascular risk in renal disease patients.
56. Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int 2005; 68:S87-S93.
57. Coimbra TM, Janssen U, Grone HJ, et al. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000; 57:167-182.
58. Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58:293-301.
59. Samuelsson O, Mulec H, Knight-Gibson C, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12:1908-1915.
60. Mahley RW, Huang Y. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 1999; 10:207-217.
61. Liberopoulos EN, Miltiadous GA, Cariolou M, et al. Influence of apolipoprotein E polymorphisms on serum creatinine levels and predicted glomerular filtration rate in healthy subjects. Nephrol Dial Transplant 2004; 19:2006-2012.
62. Oda H, Yorioka N, Ueda C, et al. Apolipoprotein E polymorphism and renal disease. Kidney Int Suppl 1999; 71:S25-S27.
63. Yorioka N, Nishida Y, Oda H, et al. Apolipoprotein E polymorphism in IgA nephropathy. Nephron 1999; 83:246-249.
64. Wilson PW, Myers RH, Larson MG, et al. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. J Am Med Assoc 1994; 272:1666-1671.
65. Hsu CC, Kao WH, Coresh J, et al. Apolipoprotein E and progression of chronic kidney disease. J Am Med Assoc 2005; 293:2892-2899.
66. Araki S, Koya D, Makiishi T, et al. APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes: results of a prospective observational follow-up study. Diabetes Care 2003; 26:2416-2420.
67. Eto M, Saito M, Okada M, et al. Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis 2002; 40:243-251.
68. Boizel R, Benhamou PY, Corticelli P, et al. ApoE polymorphism and albuminuria in diabetes mellitus: a role for LDL in the development of nephropathy in NIDDM? Nephrol Dial Transplant 1998; 13:72-75.
69. Liberopoulos E, Siamopoulos K, Elisaf M. Apolipoprotein E and renal disease. Am J Kidney Dis 2004; 43:223-233.
70. Vidt DG, Cressman MD, Harris S, et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004; 102:52-60.
71. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006; 17:2006-2016. Meta-analysis reporting statin induced favorable renal outcome and reduction of proteinuria.
72. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
73. Schwartz GG, Olsson AG, Ezekowitz MD, et al., for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL Study: a randomized controlled trial. J Am Med Assoc 2001; 285:1711-1718.
74. De Lemos JA, Blazing MA, Wiviott SD, et al., for the A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z Trial. J Am Med Assoc 2004; 292:1307-1316.
75. Nissen SE. High-dose statins in acute coronary syndromes: not just lipid levels. J Am Med Assoc 2004; 292:1365-1367.
76. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6:1399-1402.
77. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420:78-84.
78. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7:687-692.
79. Rezaie-Majd A, Prager GW, Bucek RA, et al. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2003; 23:397-403.
80. Kumar AP, Reynolds WF. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun 2005; 331:442-451.
81. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003; 108:426-431.
82. Chung HK, Lee IK, Kang H, et al. Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol Med 2002; 34:451-461.
83. Laufs U, Wassmann S, Hilgers S, et al. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001; 88:1306-1307.
84. Kelynack KJ, Hewitson TD, Martic M, et al. Lovastatin downregulates renal myofibroblast function in vitro. Nephron 2002; 91:701-707.
85. Mauro VJ Jr, Mantovani E, Tavares RL, et al. Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol Dial Transplant 2005; 20:1582-1591.
86. Panichi V, Paoletti S, Mantuano E, et al. In vivo and in vitro effects of simvastatin on inflammatory markers in predialysis patients. Nephrol Dial Transplant 2006; 21:337-344.
87. Verma A, Ranganna KM, Reddy RS, et al. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol 2005; 96:1290-1292.
88. Van Dijk MA, Kamper AM, van Veen S, et al. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001; 16:2152-2157.
89. Eddy AA. Proteinuria and interstitial injury. Nephrol Dial Transplant 2004; 19:277-281.
90. Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as a modifiable risk factor for the progression of nondiabetic renal disease. Kidney Int 2001; 60:1131-1140.
91. Buemi M, Allegra A, Corica F, et al. Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 2000; 67:427-431.
92. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41:565-570.
93. Vidt DG. Statins and proteinuria. Curr Atheroscler Rep 2005; 7:351-357.
94. Nakamura T, Ushiyama C, Hirokawa K, et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 2002; 17:798-802.
95. Ozsoy RC, Koopman MG, Kastelein JJ, Arisz L. The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritis. Clin Nephrol 2005; 63:245-249.
96. Asselbergs FW, Diercks GFH, Hillege HL, et al., for the Prevention of Renal and Vascular Endstage Disease Intervention Trial Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110:2809-2816.
97. Atthobari J, Brantsma AH, Gansevoort RT, et al., on behalf of PREVEND study group. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. May 23, 2006 [Epub ahead of print].
98. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006; 145:117-124. Meta-analysis on the statin induced reduction of proteinuria.
99. Agarwal R. Statin induced proteinuria: renal injury or renoprotection? J Am Soc Nephrol 2004; 15:2502-2503.
100. Kasiske BL, Wanner C, O'Neill WC. An assessment of statin safety by nephrologists. Am J Cardiol 2006; 97:S82-S85.